Timothy Kubal, MD, MBA

Cancer Focus:
Benign Hematology, Leukemia, Myelodysplastic Syndromes (MDS)

Dr. Kubal is the Chair of the Department of Ambulatory Hematology and Oncology at Moffitt Cancer Center. He completed his hematology/oncology fellowship at the University of South Florida at Moffitt Cancer Center, completing an MBA concurrently at the University of South Florida. Dr. Kubal's research and clinical interests are in benign and malignant hematology. In addition to his clinical efforts, Dr. Kubal is focused on continuous improvement of the patient experience. Dr. Kubal practices full time at the Moffitt Wesley Chapel campus.

Education & Training

Fellowship:

• Moffitt Cancer Center/University of South Florida - Hematology/Oncology

Residency:

• University of North Carolina - Internal Medicine

Medical School:

• Florida State University College of Medicine - MD

• Patil N, Ravichandran S, Messina J, Kirtane K, Phuoc V, Kubal T, Maharaj S. Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review. EJHaem. 2025 Aug.6(4):e70094. Pubmedid: 40625824. Pmcid: PMC12232973.
• Streiff MB, Holmstrom B, Angelini D, Ashrani A, Buckner T, Diep R, Fertrin KY, Fogerty AE, Crestani NG, Gangaraju R, Rojas-Hernandez C, Goldhaber SZ, Ibrahim I, Kubal T, Leavitt AD, Lim M, Mann J, Mantha S, Morton C, Nester A, O'Brien A, Ortel TL, Pine A, Pishko A, Ranade M, Salmasi A, Schaefer J, Williams E, Wool G, Wun T, Montgomery S, Nguyen J, Freedman-Cass D, Sliker B. Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2024 Sep.22(7):483-506. Pubmedid: 39236759.
• Mathew S, Kubal T, Tabatabaian F. Worsening hypereosinophilia with use of dupilumab. Ann Allergy Asthma Immunol. 2023 Mar.130(3):272-275. Pubmedid: 36513222.
• Krause D, Sharrah K, Gross A, Bowers D, Mulkerin D, Brandt N, Kennedy K, Austin A, Begue A, Bell R, Raczyk C, Pickard T, Kubal T, Johnson D, Jeffries K, Dest V, Randall R, Sugalski J, Zecha G. Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network's Member Institutions. J Adv Pract Oncol. 2022 Jul.13(5):507-513. Pubmedid: 35910498. Pmcid: PMC9328455.
• Sugalski JM, Franco T, Shulman LN, Souza E, Hochberg E, Chiang A, Lawrence S, Krause D, Kubal T. COVID-19 and Cancer Center Operations: Lessons Learned From the NCCN Best Practices Committee. J Natl Compr Canc Ne. 2022 Jan.20(13). Pubmedid: 34991065.
• Li W, Richter K, Lee J, McCarthy K, Kubal T. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2022 Dec.28(8):1812-1818. Pubmedid: 34609924.
• Li W, Richter KA, Tobon KA, McCarthy KT, Kubal TE. Safety and financial analysis of outpatient dose-adjusted EPOCH for B-cell lymphoma at a tertiary comprehensive cancer center. J Oncol Pharm Pract. 2021 Oct.27(7):1684-1690. Pubmedid: 33092499.
• Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
• Mason NT, Burkett JM, Nelson RS, Pow-Sang JM, Gatenby RA, Kubal T, Peabody JW, Letson GD, McLeod HL, Zhang J. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. Am Health Drug Benefits. 2021 Mar.14(1):15-20. Pubmedid: 33841621. Pmcid: PMC8025923.
• Sugalski J, Franco T, Shulman LN, Cinar P, Bachman J, Crews JR, Olsen M, Schatz A, Kubal T. Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care. J Natl Compr Canc Ne. 2020 Oct.1-5. Pubmedid: 33126204.
• Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: 31549389. Pmcid: PMC7018540.
• Talati C, Frantz D, Lubas A, Salamanca C, Tobon K, Kubal T. How I treat newly diagnosed acute myeloid leukemia in an outpatient setting: a multidisciplinary team perspective. Future Oncol. 2020 Mar.16(7):281-291. Pubmedid: 31985277.
• Cinar P, Kubal T, Freifeld A, Mishra A, Shulman L, Bachman J, Fonseca R, Uronis H, Klemanski D, Slusser K, Lunning M, Liu C. Safety at the Time of the COVID-19 Pandemic: How to Keep our Oncology Patients and Healthcare Workers Safe. J Natl Compr Canc Ne. 2020 Apr.1-6. Pubmedid: 32294617.
• Johnson D, Ouenes O, Letson D, de Belen E, Kubal T, Czarnecki C, Weems L, Box B, Paculdo D, Peabody J. A Direct Comparison of the Clinical Practice Patterns of Advanced Practice Providers and Doctors. Am J Med. 2019 Nov.132(11):e778-e785. Pubmedid: 31145882.
• Sugalski JM, Kubal T, Mulkerin DL, Caires RL, Moore PJ, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA, Kidd SK, Krause DM, Carlson RW, Stewart FM. National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers. J Oncol Pract. 2019 May.15(5):e458-e466. Pubmedid: 30964732.
• Colonna S, Sweetenham J, Burgon TB, Buys SS, Lynch R, Au T, Johnson E, Kubal T, Paculdo D, Acelajado MC, Peabody JW. A Better Pathway? Building Consensus and Engaging Providers with Feedback to Improve and Standardize Cancer Care. Clin Breast Cancer. 2019 Apr.19(2):e376-e384. Pubmedid: 30711440.
• Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar.92(3):232-237. Pubmedid: 28006850.
• Kubal T, Letson DG, Chiappori AA, Springett GM, Shimkhada R, Tamondong Lachica D, Peabody JW. Longitudinal cohort study to determine effectiveness of a novel simulated case and feedback system to improve clinical pathway adherence in breast, lung and GI cancers. BMJ Open. 2016 Sep.6(9):e012312. Pubmedid: 27625063. Pmcid: PMC5030551.
• Kubal T, Peabody JW, Friedman E, Levine R, Pursell S, Letson DG. Using Vignettes to Measure and Encourage Adherence to Clinical Pathways in a Quality-Based Oncology Network: An Early Report on the Moffitt Oncology Network Initiative. Manag Care. 2015 Oct.24(10):56-64. Pubmedid: 26665718.
• Dalia S, Sagatys E, Sokol L, Kubal T. Rosai-Dorfman disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014 Oct.21(4):322-327. Pubmedid: 25310213.
• Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol. 2013 Mar.20(2):100-106. Pubmedid: 23385612.
• Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun.11(2):85-87. Pubmedid: 22169039.
• Winokur RS, Kubal T, Liu D, Davis SF, Smith BN. Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy. Epilepsy Res. 2004 Feb.58(2-3):93-105. Pubmedid: 15120741.

Voted top doctor in Hematology/Oncology in Tampa Magazine’s Top Doctors 2025.